← All trials
NCT07289971
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2026
- Primary completion
- Mar 31, 2026
- Completion date
- May 31, 2026
- First posted
- Dec 17, 2025
- Last posted
- Dec 17, 2025
- Enrollment
- 96
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Health Sciences LahoreLead sponsor
- University of Health Sciences LahoreSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.